Rhumbline Advisers Werewolf Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 31,231 shares of HOWL stock, worth $24,047. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,231
Previous 28,916
8.01%
Holding current value
$24,047
Previous $42,000
26.19%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding HOWL
# of Institutions
72Shares Held
28MCall Options Held
12KPut Options Held
14K-
Ra Capital Management, L.P. Boston, MA6.14MShares$4.73 Million0.15% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$3.3 Million5.1% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.91MShares$2.24 Million0.28% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$1.84 Million0.53% of portfolio
-
Bank Of America Corp Charlotte, NC2.08MShares$1.6 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $22.7M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...